31 results about "Complement Factor D" patented technology

The present invention provides methods for identifying a patient at risk for developing AMD by identifying the presence of the Y402H polymorphism or other at risk variants in the complement factor H gene. The present invention further provides methods for treating persons having AMD or at risk for developing AMD as a result of having the Y402H polymorphism or other at risk variants in the complement factor H gene.

Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R12 or R13 on the A group is an amide substituent (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade in the alternative complement pathway. The inhibitors of factor D described herein reduce the excessive activation of complement.

Macrocyclic Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, and Formula VIII or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Arteriosclerosis induces cerebral infarction and myocardial infarction. A multi-marker (a group of protein markers) that assesses the accurate pathogenesis of arteriosclerosis and enables the selection of an adequate treatment method for arteriosclerosis and prediction of the progression of arteriosclerosis, and an evaluation method for the diagnosis, prevention, and treatment of arteriosclerosis that uses said marker group as an indicator have been sought. The present invention relates to A method for evaluation of arteriosclerosis comprising the steps of (a) measuring the expression of von Willebrand factor and / or complement factor D in a sample derived from a subject, (b) measuring the expression of complement component C8 and / or vitamin K-dependent protein Z in the sample derived from the subject, and (c) evaluating arteriosclerosis in the subject on the basis of the results from (a) and (b).

Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, and Formula IV or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Provided herein are methods for treating a subject with PNH comprising administering to a subject a therapeutically effective amount of complement component C5 (C5) inhibitor, complement component C3 (C3) inhibitor, or complement factor B (CFB) inhibitor in combination with a therapeutically effective amount of small molecule complement factor D (CFD) inhibitor of Formula I or Formula II, or a pharmaceutically acceptable salt thereof.

Macrocyclic Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, and Formula VIII or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

The application discloses methods and compositions for the inhibition of the alternative complement pathway. The methods and compositions involve the use of aptamers for inhibiting complement Factor D. The application further provides anti-Factor D aptamers for the treatment of dry age-related macular degeneration, geographic atrophy, wet age-related macular degeneration or Stargardt disease.

Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, and Formula IV or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.

The application discloses methods and compositions for the inhibition of the alternative complement pathway. The methods and compositions involve the use of aptamers for inhibiting complement Factor D. The application further provides anti-Factor D aptamers for the treatment of dry age-related macular degeneration, geographic atrophy, wet age-related macular degeneration or Stargardt disease.

Arteriosclerosis induces cerebral infarction and myocardial infarction. A multi-marker (a group of protein markers) that assesses the accurate pathogenesis of arteriosclerosis and enables the selection of an adequate treatment method for arteriosclerosis and prediction of the progression of arteriosclerosis, and an evaluation method for the diagnosis, prevention, and treatment of arteriosclerosis that uses said marker group as an indicator have been sought. The present invention relates to A method for evaluation of arteriosclerosis comprising the steps of (a) measuring the expression of von Willebrand factor and / or complement factor D in a sample derived from a subject, (b) measuring the expression of complement component C8 and / or vitamin K-dependent protein Z in the sample derived from the subject, and (c) evaluating arteriosclerosis in the subject on the basis of the results from (a) and (b).

This invention provides stable, highly crystalline forms of Complement factor D inhibitors Compound 1 and Compound 2 for advantageous therapeutic pharmaceutical efficacy and dosage form stability.

Disclosed are compounds of Formula (I)-(IV) and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such compounds, and methods of using the compounds and compositions to treat or prevent diseases or conditions characterized by aberrant complement system activity.

Compounds and pharmaceutically acceptable salts and prodrugs thereof are disclosed, which are inhibitors of the complement system. Also provided are oral dosage forms comprising such compounds, salts, or prodrugs. Also disclosed are methods of using the compounds, salts and prodrugs and oral dosage forms thereof to treat or prevent diseases or conditions characterized by aberrant complement system activity (e.g., paroxysmal sleep hemoglobinuria).

A preeclampsia detecting kit using Adipsin as indicator, comprises porous plate coated with anti-human Adipsin monoclonal antibody, anti-human Adipsin monoclonal antibody detecting solution marked by biotin, avidin horseradish peroxidase combined with anti-human Adipsin monoclonal antibody marked by biotin, chromogenic substrate 3',3',5,5'-tetramethylbenzidine and Adipsin protein standard substance. The preparing method of the detecting kit comprises:(1)preparing the porous plate coated with anti-human Adipsin monoclonal antibody; (2) preparing the anti-human Adipsin monoclonal antibody detecting solution marked by biotin;(3) preparing the avidin horseradish peroxidase combined with anti-human Adipsin monoclonal antibody marked by biotin;(4) preparing the chromogenic substrate 3',3',5,5'-tetramethylbenzidine and Adipsin protein standard substance.

It is intended to evaluate an ischemic heart disease with high accuracy by convenient operation. The method for evaluating an ischemic heart disease according to the present invention comprises the steps of: assaying complement factor H and / or complement factor D in a sample derived from the blood of a test subject; and comparing the concentration of the complement factor H and / or the concentration of the complement factor D assayed in the preceding step with a reference value(s), wherein it is determined that the seriousness of the ischemic heart disease is high when the concentration falls below the reference value.

The present invention discloses an anti-complement factor D humanized Fab and humanized antibody and application thereof, the humanized Fab and humanized antibody contain light chain variable region and heavy chain variable region, the use Human complement factor D-related diseases are diseases caused by elevated human complement factor D.

The application discloses methods and compositions for the inhibition of the alternative complement pathway. The methods and compositions involve the use of aptamers for inhibiting complement Factor D. The application further provides anti-Factor D aptamers for the treatment of dry age-related macular degeneration, geographic atrophy, wet age-related macular degeneration or Stargardt disease. In some cases, stem-loop aptamers are provided for the inhibition of Factor D.

This invention provides stable, highly crystalline forms of Complement Factor D inhibitor Compound 3 for therapeutic applications.

A means for rapidly detecting Adipsin for diagnosing preeclampsia comprises a water-adsorbing pad(2), a nitrocellulose membrane(5), a gold labeling pad (6) and a sampling pad (7), all of which are successively joined from the top down and fixed in the base plate(1). The gold-labeling pad (6) is partly overlapped by the sampling pad (7). A detecting line (4) coated by rabbit anti-human Adipsin polyclonal antibody, or goat anti-human Adipsin polyclonal antibody or mouse anti-human Adipsin polyclonal antibody and a controlling line (3) coated by goat anti-mouse IgG polyclonal antibody are provided on the nitrocellulose membrane (5). The detecting line (4) is located downstream and spaced from the controlling line (3).The gold-labeling pad (6) is made of water adsorbing material, and coated by gold labeled mouse anti-human Adispin monoclonal antibody. A tesk kit for rapidly detecting Adipsin for diagnosing preeclampsia comprises an outer house (8) and the said means therein. The method for preparing the said detecting means comprise: 1) coating of the detecting line (4) and the controlling line (3); 2) preparing the gold labeling pad (6); 3)combination.

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.

The invention provides a marker for predicting the curative effect of harmful ventricular remodeling and immunotherapy of myocardial infarction patients and application of the marker. The marker comprises granular protein, galectin 3, a complement factor D, a cysteine protease inhibitor 3 and C1q, the five markers are combined to be used as serum indexes for predicting harmful ventricular remodeling and immunotherapy curative effects of myocardial infarction patients, so that the requirements on specificity, accuracy, precision (including repeatability, day difference and personnel operation error) and the like in a verification process can be met; the method has important significance in predicting harmful ventricular remodeling and immunotherapy effects of myocardial infarction patients.

Compounds of Formula (I) and pharmaceutically acceptable salts thereof are disclosed, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such compounds, and methods of using the compounds and compositions to treat or prevent diseases or conditions characterized by aberrant complement system activity.